286 results
8-K
OTLC
Oncotelic Therapeutics, Inc.
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
. [ ]
Item 1.01 Entry into a Material Definitive Agreement.
Expanded Access Program (EAP) Master Service Agreement between myTomorrow and Mateon … and the urgency of the global situation early on, Mateon’s has engaged myTomorrows as a regulatory intelligence asset and pre-approval access expert
8-K
EX-10.3
OTLC
Oncotelic Therapeutics, Inc.
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
and Manufacturer, respectively, in a U.S. Expanded Access Program for treatment use of OT-101 in 25 or more cancer patients (“USEAPOT101”), as defined … and agreed to under the Parties’ Investigational Product Supply and Use Authorization Agreement for OT-101 U.S. Expanded Access (“IPSUA
8-K
EX-10.2
OTLC
Oncotelic Therapeutics, Inc.
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
Agreement for Delivery and Licensed Use of Data Generated from OT-101 U.S. Expanded Access
(Data License 1 Agreement)
between WideTrial … to collaborate as Sponsor and Manufacturer, respectively, in a U.S. Expanded Access Program for treatment use of OT-101 for 25 or more patients
8-K
OTLC
Oncotelic Therapeutics, Inc.
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
., a Delaware corporation (“WideTrial”) for an Expanded Access Program to evaluated Oncotelic’s therapeutic product candidate OT-101 for the treatment … of pancreatic cancer, as well as data access through license agreements. Each of the agreements is summarized below:
Investigational Product Supply and Use
8-K
EX-99.1
OTLC
Oncotelic Therapeutics, Inc.
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
AGOURA HILLS, California and SAN FRANCISCO, California … , September 9th, 2019 -- Mateon Therapeutics Inc. (OTCQB:MATN), announced today that it has executed agreements with WideTrial Inc. for an Expanded Access
8-K
EX-10.1
5s25jrv8mnfs 8i3pt
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
EX-10.1
j6kgqgi7
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
8-K
EX-10.4
iv5v7hnq5j3pj 6lbh
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
EX-10.2
wl9mh5h4ehfqb
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
424B3
pgpn vd034keo
9 Dec 09
Prospectus supplement
12:00am
8-K
EX-99.1
ffqzb
5 May 08
OXiGENE Reports First Quarter 2008 Results
12:00am
8-K
EX-10.2
eul38o
16 Jun 20
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic Bio
6:58am
8-K
EX-99
f40 5umv623
12 Dec 11
Other Events
12:00am